NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled trial of omega-3 polyunsaturated fatty acids (PUFA) in ultra-high risk for psychosis (UHR) patients. Primary outcomes of interest were transition to psychosis and symptomatic and functional outcome. A secondary aim was to investigate clinical predictors of medium-term outcome. Three hundred four UHR participants were recruited across 10 specialised early psychosis services in Australia, Asia, and Europe. The intervention consisted of 1.4 g/daily of omega-3 PUFA or placebo, plus up to 20 sessions of cognitive-behavioural case management (CBCM), over the 6-month study period, with participants receiving further CBCM sessions on basis of need between months 6-12. Mean time to follow-up was 3.4 (median = 3.3; SD = 0.9) years. There was a modest increase in transitions between 12-month and medium-term follow-up (11-13%) and substantial improvement in symptoms and functioning between baseline and follow-up, with no differences between the treatment groups. Most improvement had been achieved by end of the intervention. 55% of the sample received mental health treatment between end of intervention and follow-up. Omega-3 PUFA did not provide additional benefits to good quality psychosocial intervention over the medium term. Although most improvement had been achieved by end of intervention the substantial rates of post-intervention mental health service use indicate longer-term clinical need in UHR patients. The post-intervention phase treatment or the longer-term effect of CBCM, or a combination of the two, may have contributed to maintaining the gains achieved during the intervention phase and prevented significant deterioration after this time.
Source: Schizophrenia
Institutions: The University of Melbourne, Orygen, Medical University of Vienna, Jena University Hospital, The University of Sydney, Kanton Zürich, University of Hong Kong, Amsterdam UMC Location University of Amsterdam, Bispebjerg Hospital, Universitäre Psychiatrische Kliniken Basel, Institute of Mental Health, University of Warwick, Coventry and Warwickshire Partnership NHS Trust, Greater Manchester Mental Health NHS Foundation Trust, University of Manchester
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,590
Awards: Predictors of Outcome and Intervention in the ‘Ultra-High Risk’ for Psychosis Population, G3551436381, Uncoupled Research Fellowship, Emerging Mental Disorders in Young People: Using Clinical Staging for Prediction, Prevention and Early Intervention, Mapping and treating early clinical stages of mental disorders during transition to adulthood, NIHR Senior Investigator Award, G6176669848, SMRI Treatment Trial 07TGF-1102: omega-3 for schizophrenia, Lipid biology for prediction and prevention of psychotic disorders and persistent depression in young people
OpenAlex ID: W2809103440